Dual HER2 Blockade and Metronomic Chemotherapy Active and Safe for Elderly Patients With HER2-Positive, Metastatic Breast Cancer

Although elderly patients account for more than one-third of advanced breast cancer cases, data about optimal treatment options for these patients are limited, as these patients are largely underrepresented in clinical trials. For younger patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer, dual HER2 blockade with the antibodies pertuzumab and trastuzumab[…]

Read More

prIME LINES BRAF-rechallenge-for-metastatic-melanoma

Rechallenge With BRAF-Inhibitor-Based Therapy Is Clinically Meaningful in BRAF-Mutant Metastatic Melanoma

For patients with metastatic melanoma with BRAFV600E mutations, treatment with the combination of a BRAF inhibitor (BRAFi) and a MEK inhibitor (MEKi) is a standard of care. While these agents induce high response rates, the majority of responding patients acquire resistance within 15 months of treatment initiation, leading to disease progression. Immunotherapy is an effective[…]

Read More

Increased cancer cell growth

Pembrolizumab Effective in Thymic Carcinoma

Thymic carcinoma is a rare, aggressive cancer with few treatment options. Chemotherapy is the primary treatment for metastatic thymic carcinoma, but it is associated with high rates of relapse. Targeted therapies, with the exception of sunitinib, have been largely unsuccessful treatments for this disease. Thymic carcinomas have high PD-L1 expression, making immunotherapy with anti–PD-1/PD-L1 antibodies[…]

Read More


Apalutamide: A Potential New Standard of Care for Nonmetastatic Castration-Resistant Prostate Cancer

Despite advances in treatment, metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease, with a median survival of approximately 2.5 years. mCRPC can develop from either metastatic hormone-sensitive prostate cancer, or from nonmetastatic prostate cancer that has developed resistance to androgen deprivation therapy (ADT).  Since metastases are a major cause of complications and death in[…]

Read More

FDA, breast cancer, BRCA, olaparib, NSCLC, afatinib, neuroendocrine tumors, GEP-NET

FDA Approved Three New Oncology Indications in January

Olaparib Given Greenlight in BRCA-Mutated Breast Cancer. The poly (ADP-ribose) polymerase (PARP) inhibitor olaparib (Lynparza®, AstraZeneca) was approved for use in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer who have previously been treated with chemotherapy and, if appropriate, a hormonal therapy. This approval was based on results from the phase III OlympiAD trial, in[…]

Read More

Colorectal cancer

Atezolizumab and Cobimetinib Combination Effective in Microsatellite-Stable Colorectal Cancer

Immunotherapy with antibodies targeting programmed death receptor 1 (PD-1) and its ligand (PD-L1) has changed the standard of care for many tumor types, including metastatic colorectal cancer (mCRC) with high levels of microsatellite instabilities (MSI-H). Unfortunately, only around 5% of patients with mCRC have an MSI-H genotype, while the remaining 95% are microsatellite stable (MSS).[…]

Read More


Impressive Antitumor Activity With Pembrolizumab in Unresectable, Previously Treated Hepatocellular Carcinoma

Advanced, unresectable hepatocellular carcinoma (HCC) is an aggressive, difficult-to-treat disease with poor prognosis and short survival time. Until recently, sorafenib was the only approved treatment option for this malignancy. However, treatment options expanded in 2017 with the approval of the multikinase inhibitor regorafenib and the first immunotherapy, the PD-1 inhibitor nivolumab, for patients progressing on[…]

Read More

NGS Sequencing

Tumor Mutation Burden by Targeted Next Generation Sequencing Predicts Benefit to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer

Introduction of immune checkpoint inhibitors has revolutionized the treatment of non-small cell lung cancer (NSCLC), but only subset of patients responds to these agents and there remains a high unmet need for effective biomarkers that can accurately predict which patients may benefit from immunotherapy. Currently, high levels of microsatellite instability and expression of PD-L1 are[…]

Read More


CAR T Cells Continue to Impress in Refractory B-Cell Lymphoma

One of the biggest breakthroughs of 2017 was the approval of two novel chimeric antigen receptor T-cell (CAR T-cell) therapies, tisagenlecleucel and axicabtagene ciloleucel, for the treatment of certain B-cell hematologic malignancies. CAR T cells represent the next generation of immunotherapy and continue to be an area of active research. At the 2017 American Society[…]

Read More


Mogamulizumab Shines in Relapsed Cutaneous T-Cell Lymphoma

Cutaneous T-cell lymphoma (CTCL) is a less common subtype of non-Hodgkin lymphoma (NHL) for which there are relatively few effective treatment options. Mogamulizumab is a monoclonal antibody targeting chemokine receptor 4 (CCR4), a receptor that is frequently overexpressed on CTCL cells. In a phase I/II trial, mogamulizumab was found to be safe and effective in[…]

Read More